Personalis (PSNL) Set to Announce Earnings on Wednesday

Personalis (NASDAQ:PSNL) is scheduled to post its quarterly earnings results after the market closes on Wednesday, November 6th. Analysts expect Personalis to post earnings of ($0.33) per share for the quarter. Personalis has set its FY 2024 guidance at EPS and its Q3 2024 guidance at EPS.Investors that wish to listen to the company’s conference call can do so using this link.

Personalis (NASDAQ:PSNL) last announced its earnings results on Wednesday, August 7th. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.10. The business had revenue of $22.58 million for the quarter, compared to the consensus estimate of $19.81 million. Personalis had a negative net margin of 101.78% and a negative return on equity of 56.87%. During the same quarter in the prior year, the firm posted ($0.50) earnings per share. On average, analysts expect Personalis to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Personalis Trading Up 0.8 %

Personalis stock opened at $5.09 on Monday. Personalis has a 12-month low of $0.89 and a 12-month high of $7.20. The firm has a 50-day moving average price of $5.20 and a 200-day moving average price of $3.22. The firm has a market capitalization of $270.18 million, a PE ratio of -3.10 and a beta of 1.94.

Analysts Set New Price Targets

Several brokerages have issued reports on PSNL. Needham & Company LLC raised their price objective on shares of Personalis from $5.50 to $7.25 and gave the stock a “buy” rating in a research note on Friday, August 16th. HC Wainwright raised their price target on Personalis from $7.50 to $9.00 and gave the stock a “buy” rating in a research note on Monday, August 19th. Finally, BTIG Research upped their price objective on Personalis from $5.50 to $7.00 and gave the company a “buy” rating in a research report on Friday, August 16th.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.